Gastroenterology · Clinical trials
Ulcerative Colitis Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About ulcerative colitis — and why its trials are hard
Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease characterised by continuous mucosal inflammation of the colon and rectum, causing bloody diarrhoea, urgency, tenesmus and abdominal pain, with risk of colectomy and colorectal cancer. Treatment is stepwise: 5-aminosalicylates (mesalamine) for mild-to-moderate disease, corticosteroids for flares, and thiopurines as maintenance. Moderate-to-severe disease is now served by an expanding array of advanced therapies. Anti-TNF agents led the way with infliximab (ACT-1/ACT-2), followed by the gut-selective anti-integrin vedolizumab (GEMINI), the IL-12/23 inhibitor ustekinumab (UNIFI), and the newer IL-23p19 inhibitor mirikizumab (LUCENT). Oral small molecules include the JAK inhibitors tofacitinib (OCTAVE) and upadacitinib (U-ACHIEVE/U-ACCOMPLISH), and the sphingosine-1-phosphate receptor modulators ozanimod (True North) and etrasimod (ELEVATE UC). Endpoints have evolved from clinical response toward clinical remission, endoscopic improvement and increasingly histologic remission. Despite the crowded landscape, some agents such as etrolizumab failed to consistently meet pivotal endpoints, underscoring the difficulty of durable mucosal healing.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Infliximab (Remicade) | 2005 | Moderate-to-severe UC (induction and maintenance) | ACT-1 and ACT-2 (phase 3, NEJM 2005) | Clinical response at week 8 (and sustained response/remission) | Clinical response ~61-69% vs ~29-37% placebo at week 8 (p<0.001) |
| Vedolizumab (Entyvio) | 2014 | Moderate-to-severe UC; gut-selective anti-a4b7 integrin | GEMINI 1 (phase 3, NEJM 2013) | Clinical response at week 6 and clinical remission at week 52 | Week 6 response ~47% vs ~26% placebo; higher week-52 remission vs placebo (p<0.001) |
| Ustekinumab (Stelara) | 2019 | Moderate-to-severe UC; anti-IL-12/23 p40 | UNIFI (phase 3, NEJM 2019) | Clinical remission at week 8 (induction) and week 44 (maintenance) | Significantly higher remission versus placebo at both induction and maintenance (p<0.001) |
| Tofacitinib (Xeljanz) | 2018 | Moderate-to-severe UC; oral JAK inhibitor | OCTAVE Induction 1 & 2 and OCTAVE Sustain (phase 3, NEJM 2017) | Clinical remission at week 8 (induction) and week 52 (maintenance) | Remission ~18% vs ~8% placebo at induction; ~34-41% vs ~11% at week 52 (p<0.001) |
| Ozanimod (Zeposia) | 2021 | Moderate-to-severe UC; oral S1P receptor modulator | True North (phase 3, NEJM 2021) | Clinical remission at week 10 (induction) and week 52 (maintenance) | Remission ~18% vs ~6% placebo induction; ~37% vs ~19% at week 52 (p<0.001) |
| Upadacitinib (Rinvoq) | 2022 | Moderate-to-severe UC; oral selective JAK1 inhibitor | U-ACHIEVE and U-ACCOMPLISH (phase 3, Lancet 2022) | Clinical remission at week 8 (induction) and week 52 (maintenance) | Robust remission benefit over placebo at induction and maintenance (p<0.001) |
| Mirikizumab (Omvoh) | 2023 | Moderate-to-severe UC; anti-IL-23 p19 | LUCENT-1 (induction) and LUCENT-2 (maintenance) (phase 3, NEJM 2023) | Clinical remission at week 12 (induction) and week 40 (maintenance) | Approximately 50% of maintenance patients in remission at one year; significant vs placebo (p<0.001) |
| Etrasimod (Velsipity) | 2023 | Moderate-to-severe UC; oral S1P receptor modulator | ELEVATE UC 52 and ELEVATE UC 12 (phase 3, Lancet 2023) | Clinical remission at week 12 and week 52 | Significantly higher clinical remission versus placebo at both timepoints (p<0.001) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in ulcerative colitis development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Etrolizumab — Phase 3 programme including HICKORY, LAUREL and HIBISCUS (anti-b7 integrin) | Inconsistent results across the programme; failed to consistently meet primary endpoints (e.g., maintenance remission), and development for UC was discontinued | Mixed induction/maintenance signals across studies, heterogeneous prior-biologic exposure and possibly insufficient target engagement for durable remission |
Choosing the right endpoint
Primary endpoints that matter in ulcerative colitis trials
- Clinical remission (Mayo score) — Primary endpoint in modern UC trials, typically based on the (modified) Mayo score
- Clinical response — Reduction in Mayo score; earlier-generation primary endpoint (e.g., ACT trials)
- Endoscopic improvement/healing — Mucosal healing (Mayo endoscopic subscore 0-1); key objective endpoint
- Histologic remission — Increasingly used deeper-healing endpoint reflecting microscopic resolution
- Corticosteroid-free remission — Important maintenance endpoint indicating durable disease control
How iNGENū runs ulcerative colitis trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Ulcerative Colitis clinical trials — FAQs
What are the main classes of advanced UC therapy?
How have UC trial endpoints changed?
Have any UC drugs failed pivotal trials?
Ready to discuss your ulcerative colitis trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal